フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option PR Newswire SAN DIEGO, Oct. 25, 2013 SAN DIEGO, Oct. 25, 2013 /PRNewswire/...
Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain PR Newswire SAN DIEGO, Oct. 10, 2013 SAN DIEGO, Oct...
Sorrento Therapeutics Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to...
Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer...
Sorrento Therapeutics Completes IgDraSol Merger PR Newswire SAN DIEGO, Sept. 10, 2013 SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento...
Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway Official Minutes from...
Sorrento Therapeutics Announces Reverse Split of Common Stock PR Newswire SAN DIEGO, Aug. 1, 2013 SAN DIEGO, Aug. 1, 2013 /PRNewswire/...
Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine...
Sorrento Therapeutics Receives Frost & Sullivan's Prestigious 2013 Global Investment Opportunity Award in the Oncology Market PR...
Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology PR Newswire SAN DIEGO, June 6, 2013...
Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City PR Newswire SAN DIEGO, May 30, 2013 SAN...
Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the...
Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq™ for the European Union PR...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約